Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: Atorvastatin: 40 mg oral tablet daily for 6 weeks
Control Intervention1: Placebo of tablet Atorvastatin: 40 mg daily oral tablet for 6 weeks
Sponsors
CENTRAL INSTITUTE OF PSYCHIATRY
Eligibility
Inclusion criteria
Inclusion criteria: a) Patients admitted in the Institute and satisfying the ICD 10-DCR[1993] criteria for schizophrenia[ with illness duration more than or equal to 2 years] b) Age group of 18-50 years of both sexes c) Drug naive patients or drug free for minimum 2 weeks on oral antipsychotics & 4 weeks for depot preparation d) Those who give informed consent for participating in the study.
Exclusion criteria
Exclusion criteria: a) Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine. b) Significant medical or neurological illness including severe cardiovascular, hepatic, renal,[serum creatinine > 1.5 mg/dl], anaemia [Haemoglobin 8 | P a g e d) BMI >30 kg/m2 e) Not willing to give written informed consent f) Current treatment with Insulin, medications known to affect glucose tolerance anti-inflammatory drugs including NSAIDS, thiazide diuretics, agents that induce weight loss]. g) Current treatment with drugs that induce or inhibit metabolism of statins [Azole antifungals, Macrolide antibiotics, Carbamazepine, anti-retroviral protease inhibitors] h) Known hypersensitivity to Tab. Atorvastatin or any of its components i) Any current systemic infection/ inflammation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in positive,negative,cognitive symptomsof Schizophrenia and decrease in the level of C Reactive ProteinTimepoint: 2 weeks,6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the metabolic profile of the patientsTimepoint: 2 weeks, 6 weeks | — |
Countries
India
Contacts
Public ContactDebasmita Dey
CENTRAL INSTITUTE OF PSYCHIATRY
Outcome results
None listed